

Internal Medicine  
Specialised Endocrinology  
Specialised Endocrinology Services (Adult)

A03/S/a

| Code   | Metric   | Numerator  | Denominator  | Period Type    | Frequency | Data Source Numerator | Data Source Denominator | Target | Notes   | Q1              | Q2              | Q3              | Q4              |
|--------|--|--|--|----------------|-----------|-----------------------|-------------------------|--------|---|-----------------|-----------------|-----------------|-----------------|
| END08c | Mean length of stay (LOS) in days following Pituitary surgery for Cushing's  | Length of stay (in days) following procedure (excluding ITU days)  | Number of patients having Pituitary surgery for Cushing's, within the reporting period   | Rolling annual | Quarterly | Provider              | Provider                |        | Note: The CRG have confirmed for the denominator include procedure code B041 for ALL pituitary operations and Primary diagnosis D352 (benign neoplasm of pituitary gland) AND Secondary Diagnosis E240 (Cushing's) for ALL pituitary diagnoses. | Jul-21 - Jun-22 | Oct-21 - Sep-22 | Jan-22 - Dec-22 | Apr-22 - Mar-23 |
| END18  | Proportion of paediatric patients leaving the paediatric service seen by the adult endocrinology team prior to transfer to adult services  | From the denominator, the number of paediatric patients leaving the paediatric service and seen by the adult endocrinology team prior to transfer to adult services  | Number of paediatric patients leaving the paediatric service and transferred to the adult service, within the reporting period               | Quarter        | Quarterly | Provider              | Provider                |        |   | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 | Jan-23 - Mar-23 |
| END21  | Proportion of new patients with neuroendocrine tumours discussed at MDT  | Of those in the denominator, the number of patients discussed at MDT   | The total number of new patients with neuroendocrine tumours in the reporting period   | Quarter        | Quarterly | Provider              | Provider                |        |   | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 | Jan-23 - Mar-23 |
| END22  | Proportion of new pituitary patients discussed at the MDT meeting  | Of those in the denominator, the number of patients discussed at MDT.  | The total number of new pituitary patients in the reporting period   | Quarter        | Quarterly | Provider              | Provider                |        | Hyperprolactinaemia is defined as greater than 3000 mU/L<br>Include all microadenomata  | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 | Jan-23 - Mar-23 |
| END23  | Mean time (in days) from patient agreeing to surgery to pituitary surgery being undertaken (Cushing's, pituitary visual compression & pituitary bleeding)  | Total sum of all days from patient agreeing to surgery to pituitary surgery taking place   | The total number of patients having pituitary surgery (Cushing's, pituitary visual compression & pituitary bleeding) in the reporting period | Quarter        | Quarterly | Provider              | Provider                |        |   | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 | Jan-23 - Mar-23 |
| END24  | Mean length of stay (LOS) in days following non-cancer Adrenal surgery (excluding ITU days)  | Mean length of stay (LOS) in days following non-cancer Adrenal surgery   | The total number of patients having non-cancer Adrenal surgery in reporting period   | Quarter        | Quarterly | Provider              | Provider                |        | Exclude ITU days  | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 | Jan-23 - Mar-23 |
| END26  | Proportion of patients with Cushing's Disease due to micro adenoma achieving biochemical remission as defined by a post-operative 0900h serum cortisol off steroids of <50nmol/L within 14 days of pituitary surgery.                    | Of those in the denominator, the number of patients achieving biochemical remission within 14 days of surgery  | The total number of patients having Pituitary surgery for Cushing's due to micro adenoma in reporting period                                 | Quarter        | Quarterly | Provider              | Provider                |        |   | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 | Jan-23 - Mar-23 |
| END27  | Proportion of patients with Cushing's Disease due to macro adenoma achieving biochemical remission as defined by a post-operative 0900h serum cortisol <50nmol/L within 14 days of pituitary surgery                                     | Of those in the denominator, the number of patients achieving biochemical remission within 14 days of surgery  | The total number of patients having Pituitary surgery for Cushing's due to macro adenoma in reporting period                                 | Quarter        | Quarterly | Provider              | Provider                |        |   | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 | Jan-23 - Mar-23 |
| END28  | Proportion of patients with Acromegaly due to micro adenoma achieving disease remission as assessed by normal age-adjusted serum IGF1 or suppressed GH <1ug/L on an OGTT (off both medical therapy) within 4 months of pituitary surgery | Of those in the denominator, the number of patients achieving disease remission as assessed by normal age-adjusted serum IGF1 or suppressed GH <1ug/L on an OGTT (off both medical therapy) within 4 months of surgery | The total number of patients with Acromegaly due to micro adenoma having Pituitary surgery in reporting period                               | Quarter        | Quarterly | Provider              | Provider                |        |   | Jan-22 - Mar-22 | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 |

Internal Medicine  
Specialised Endocrinology  
Specialised Endocrinology Services (Adult)

A03/S/a

| Code  | Metric   | Numerator   | Denominator   | Period Type | Frequency | Data Source Numerator | Data Source Denominator | Target | Notes                                   | Q1              | Q2              | Q3              | Q4              |
|-------|--|---|---|-------------|-----------|-----------------------|-------------------------|--------|---|-----------------|-----------------|-----------------|-----------------|
| END29 | Proportion of patients with Acromegaly due to macro adenoma achieving disease remission as assessed by normal age-adjusted serum IGF1 or suppressed GH <1ug/L on an OGTT (off both medical therapy) within 4 months of pituitary surgery | Of those in the denominator, the number of patients achieving disease remission as assessed by normal age-adjusted serum IGF1 or suppressed GH <1ug/L on an OGTT (off both medical therapy within 4 months of surgery | The total number of patients with Acromegaly due to macro adenoma having Pituitary surgery in reporting period        | Quarter     | Quarterly | Provider              | Provider                |        |   | Jan-22 - Mar-22 | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 |
| END30 | Proportion of patients under follow up in last year with chronic hypoparathyroidism  | Of those in the denominator, the number of patients who have been seen as a follow up patient in the last year  | The total number of patients with chronic hypoparathyroidism on caseload for at least a year in reporting period      | Quarter     | Quarterly | Provider              | Provider                |        |   | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 | Jan-23 - Mar-23 |
| END31 | Proportion of patients with chronic hypoparathyroidism with adjusted serum calcium measured in range 2.0 - 2.3 mmol/L  | Of those in the denominator, the number of patients who measured in range 2.0 - 2.3 mmol/L  | The total number of patients with chronic hypoparathyroidism with adjusted serum calcium measured in reporting period | Quarter     | Quarterly | Provider              | Provider                |        |   | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 | Jan-23 - Mar-23 |
| END33 | Proportion of patients with PHPT with adjusted serum calcium within reference range 6 months following first parathyroid surgery   | Of those in the denominator, the number of patients who had Primary hyperparathyroidism (PHPT) and with serum adjusted Ca within reference range 6 months following surgery   | The total number of patients having first time parathyroid surgery in the reporting period                            | Quarter     | Quarterly | Provider              | Provider                |        | Reference range for calcium 2.20 - 2.60 | Oct-21 - Dec-21 | Jan-22 - Mar-22 | Apr-22 - Jun-22 | Jul-22 - Sep-22 |
| END34 | Proportion of patients with PHPT with adjusted serum calcium within reference range 6 months following second parathyroid surgery  | Of those in the denominator, the number of patients who had Primary hyperparathyroidism (PHPT) and with serum adjusted Ca within reference range 6 months following surgery   | The total number of patients having second time parathyroid surgery in the reporting period                           | Quarter     | Quarterly | Provider              | Provider                |        | Reference range for calcium 2.20 - 2.60 | Oct-21 - Dec-21 | Jan-22 - Mar-22 | Apr-22 - Jun-22 | Jul-22 - Sep-22 |
| END35 | Proportion of patients with Turner's Syndrome who have had a cardiac MRI or transthoracic echo within the last 5 years   | Of those in the denominator, the number who have had a cardiac MRI or transthoracic echo in the last 5 years  | The total number of patients with Turner's Syndrome on caseload (for at least 5 years) in the reporting period        | Quarter     | Quarterly | Provider              | Provider                |        |   | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 | Jan-23 - Mar-23 |
| END36 | Proportion of patients recruited to a clinical trial   | Of those in the denominator, the number who are recruited to a clinical trial to include natural history studies  | The total number of specialised endocrine patients on caseload in the reporting period                                | Quarter     | Quarterly | Provider              | Provider                |        | to include natural history studies      | Apr-22 - Jun-22 | Jul-22 - Sep-22 | Oct-22 - Dec-22 | Jan-23 - Mar-23 |